Etofibrate is a fibrate produced by the combination of clofibrate ester linked to niacin. These components separate in the body slowly allowing for pharmacokinetics similar to controlled-release formulations.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Clofibrate | The risk or severity of adverse effects can be increased when Clofibrate is combined with Etofibrate. |
| Fenofibrate | The risk or severity of adverse effects can be increased when Fenofibrate is combined with Etofibrate. |
| Gemfibrozil | The risk or severity of adverse effects can be increased when Gemfibrozil is combined with Etofibrate. |
| Bezafibrate | The risk or severity of adverse effects can be increased when Bezafibrate is combined with Etofibrate. |
| Ciprofibrate | The risk or severity of adverse effects can be increased when Etofibrate is combined with Ciprofibrate. |
| Simfibrate | The risk or severity of adverse effects can be increased when Etofibrate is combined with Simfibrate. |
| Ronifibrate | The risk or severity of adverse effects can be increased when Etofibrate is combined with Ronifibrate. |
| Aluminium clofibrate | The risk or severity of adverse effects can be increased when Etofibrate is combined with Aluminium clofibrate. |
| Clofibride | The risk or severity of adverse effects can be increased when Etofibrate is combined with Clofibride. |
| Fenofibric acid | The risk or severity of adverse effects can be increased when Etofibrate is combined with Fenofibric acid. |
| Ezetimibe | The serum concentration of Ezetimibe can be increased when it is combined with Etofibrate. |
| Glycochenodeoxycholic Acid | The therapeutic efficacy of Glycochenodeoxycholic Acid can be decreased when used in combination with Etofibrate. |
| Cholic Acid | The therapeutic efficacy of Cholic Acid can be decreased when used in combination with Etofibrate. |
| Glycocholic acid | The therapeutic efficacy of Glycocholic acid can be decreased when used in combination with Etofibrate. |
| Deoxycholic acid | The therapeutic efficacy of Deoxycholic acid can be decreased when used in combination with Etofibrate. |
| Taurocholic acid | The therapeutic efficacy of Taurocholic acid can be decreased when used in combination with Etofibrate. |
| Obeticholic acid | The therapeutic efficacy of Obeticholic acid can be decreased when used in combination with Etofibrate. |
| Chenodeoxycholic acid | The therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Etofibrate. |
| Taurochenodeoxycholic acid | The therapeutic efficacy of Taurochenodeoxycholic acid can be decreased when used in combination with Etofibrate. |
| Tauroursodeoxycholic acid | The therapeutic efficacy of Tauroursodeoxycholic acid can be decreased when used in combination with Etofibrate. |
| Bamet-UD2 | The therapeutic efficacy of Bamet-UD2 can be decreased when used in combination with Etofibrate. |
| Dehydrocholic acid | The therapeutic efficacy of Dehydrocholic acid can be decreased when used in combination with Etofibrate. |
| Hyodeoxycholic Acid | The therapeutic efficacy of Hyodeoxycholic Acid can be decreased when used in combination with Etofibrate. |
| Ursodeoxycholic acid | The therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Etofibrate. |
| Cyclosporine | The risk or severity of renal failure can be increased when Cyclosporine is combined with Etofibrate. |
| Glimepiride | The risk or severity of hypoglycemia can be increased when Etofibrate is combined with Glimepiride. |
| Acetohexamide | The risk or severity of hypoglycemia can be increased when Etofibrate is combined with Acetohexamide. |
| Chlorpropamide | The risk or severity of hypoglycemia can be increased when Etofibrate is combined with Chlorpropamide. |
| Tolazamide | The risk or severity of hypoglycemia can be increased when Etofibrate is combined with Tolazamide. |
| Glyburide | The risk or severity of hypoglycemia can be increased when Etofibrate is combined with Glyburide. |
| Glipizide | The risk or severity of hypoglycemia can be increased when Etofibrate is combined with Glipizide. |
| Gliclazide | The risk or severity of hypoglycemia can be increased when Etofibrate is combined with Gliclazide. |
| Tolbutamide | The risk or severity of hypoglycemia can be increased when Etofibrate is combined with Tolbutamide. |
| Gliquidone | The risk or severity of hypoglycemia can be increased when Etofibrate is combined with Gliquidone. |
| Glisoxepide | The risk or severity of hypoglycemia can be increased when Etofibrate is combined with Glisoxepide. |
| Glibornuride | The risk or severity of hypoglycemia can be increased when Etofibrate is combined with Glibornuride. |
| Carbutamide | The risk or severity of hypoglycemia can be increased when Etofibrate is combined with Carbutamide. |
| Metahexamide | The risk or severity of hypoglycemia can be increased when Etofibrate is combined with Metahexamide. |
| Colestipol | Colestipol can cause a decrease in the absorption of Etofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sevelamer | Sevelamer can cause a decrease in the absorption of Etofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Colesevelam | Colesevelam can cause a decrease in the absorption of Etofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cholestyramine | Cholestyramine can cause a decrease in the absorption of Etofibrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dicoumarol | The risk or severity of bleeding can be increased when Etofibrate is combined with Dicoumarol. |
| Phenindione | The risk or severity of bleeding can be increased when Etofibrate is combined with Phenindione. |
| Warfarin | The risk or severity of bleeding can be increased when Etofibrate is combined with Warfarin. |
| Phenprocoumon | The risk or severity of bleeding can be increased when Etofibrate is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of bleeding can be increased when Etofibrate is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of bleeding can be increased when Etofibrate is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of bleeding can be increased when Etofibrate is combined with Coumarin. |
| (R)-warfarin | The risk or severity of bleeding can be increased when Etofibrate is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of bleeding can be increased when Etofibrate is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of bleeding can be increased when Etofibrate is combined with Fluindione. |
| Clorindione | The risk or severity of bleeding can be increased when Etofibrate is combined with Clorindione. |
| Diphenadione | The risk or severity of bleeding can be increased when Etofibrate is combined with Diphenadione. |
| Tioclomarol | The risk or severity of bleeding can be increased when Etofibrate is combined with Tioclomarol. |
| (S)-Warfarin | The risk or severity of bleeding can be increased when Etofibrate is combined with (S)-Warfarin. |
| Tacrolimus | Tacrolimus may increase the nephrotoxic activities of Etofibrate. |
| Pravastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Etofibrate is combined with Pravastatin. |
| Lovastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Etofibrate is combined with Lovastatin. |
| Cerivastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Etofibrate is combined with Cerivastatin. |
| Simvastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Etofibrate is combined with Simvastatin. |
| Atorvastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Etofibrate is combined with Atorvastatin. |
| Fluvastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Etofibrate is combined with Fluvastatin. |
| Rosuvastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Etofibrate is combined with Rosuvastatin. |
| Mevastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Etofibrate is combined with Mevastatin. |
| Pitavastatin | The risk or severity of myopathy and rhabdomyolysis can be increased when Etofibrate is combined with Pitavastatin. |
| Leuprolide | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Etofibrate. |
| Somatotropin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Etofibrate. |
| Infliximab | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Etofibrate. |
| Daptomycin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Etofibrate. |
| Baclofen | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Baclofen is combined with Etofibrate. |
| Sildenafil | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sildenafil is combined with Etofibrate. |
| Indinavir | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Indinavir is combined with Etofibrate. |
| Cladribine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Etofibrate. |
| Phenytoin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Phenytoin is combined with Etofibrate. |
| Pamidronic acid | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pamidronic acid is combined with Etofibrate. |
| Mefloquine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Mefloquine is combined with Etofibrate. |
| Tacrine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrine is combined with Etofibrate. |
| Carbimazole | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Carbimazole is combined with Etofibrate. |
| Trimethoprim | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Etofibrate. |
| Betamethasone | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Betamethasone is combined with Etofibrate. |
| Montelukast | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Montelukast is combined with Etofibrate. |
| Zidovudine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Zidovudine is combined with Etofibrate. |
| Cimetidine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cimetidine is combined with Etofibrate. |
| Ritonavir | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Etofibrate. |
| Lercanidipine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lercanidipine is combined with Etofibrate. |
| Ciprofloxacin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Etofibrate. |
| Vincristine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Etofibrate. |
| Propylthiouracil | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Etofibrate. |
| Methotrexate | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Methotrexate is combined with Etofibrate. |
| Enalapril | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Enalapril is combined with Etofibrate. |
| Nizatidine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nizatidine is combined with Etofibrate. |
| Ivermectin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ivermectin is combined with Etofibrate. |
| Chloroquine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Chloroquine is combined with Etofibrate. |
| Triamcinolone | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Triamcinolone is combined with Etofibrate. |
| Niacin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Niacin is combined with Etofibrate. |
| Alendronic acid | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Etofibrate. |
| Stavudine | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Stavudine is combined with Etofibrate. |
| Nafarelin | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nafarelin is combined with Etofibrate. |
| Amphotericin B | The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Amphotericin B is combined with Etofibrate. |